Results 31 to 40 of about 60,957 (246)

Therapeutic potential of JAK2 inhibitors [PDF]

Hematology, 2009
AbstractThe discovery of an activating tyrosine kinase mutation JAK2V617F in myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) has resulted in the development of JAK2 inhibitors, of which several are being evaluated in phase I/II clinical studies.
openaire   +2 more sources

t(9;9)(p13;p24) PAX5/JAK2 - del(9)(p13p24) PAX5/JAK2 - inv(9)(p13p24) PAX5/JAK2 [PDF]

Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2014
Short communication on t(9;9)(p13;p24) PAX5/JAK2, with data on clinics, and the genes implicated.
openaire   +2 more sources

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Simultaneous hepatosplenic T-cell lymphoma and myelofibrosis

Avicenna Journal of Medicine, 2014
Hepatosplenic T-cell lymphoma (HSTL) is a rare T-cell neoplasm of the lymphoid system. This type of lymphoma is characterized by sinusoidal infiltration of spleen, liver, bone marrow and lymph nodes by neoplastic lymphocytes.
Ali M Gabali, Tarek Jazaerly, Chung-Che Jeff Chang, Ronald Cleveland, Lawrence Kass   +4 more
doaj   +1 more source

Down‐regulation of Shh in the hair follicles of mice during chemotherapy‐induced hair loss is mediated by the JAK/STAT1 signaling pathway

FEBS Open Bio, EarlyView.
We found that during chemotherapy‐induced alopecia (CIA), Sonic hedgehog (Shh) expression significantly decreased in hair follicle Shh+ cells, whereas the Janus‐activated kinase/signal transducer and activator of transcription 1 (JAK/STAT1) signaling pathway was markedly activated.
Ruifang Fan, Jingling Huang, Xiang Lin, Tingjiao Lan, Yuli Tang, Ling Sun, Guixuan Zhou   +6 more
wiley   +1 more source

National Clinical Guidelines on Diagnosis and Treatment of Ph-Negative Myeloproliferative Neoplasms (Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis) (Edition 2024)

Клиническая онкогематология
The development of National clinical guidelines on diagnosis and treatment of Ph-negative myeloproliferative neoplasms provides the knowledge basis for decision making in diagnosis, therapy, prevention, and rehabilitation in compliance with evidence ...
Anait Levonovna Melikyan, I. N. Subortseva, A. M. Kovrigina, V. A. Shuvaev, E. V. Morozova, E. G. Lomaia, V. V. Baykov, O. Yu. Vinogradova, S. V. Gritsaev, T. I. Ionova, P. I. Kuznetsova, L. A. Kuzmina, I. S. Martynkevich, T. A. Mitina, E. S. Polushkina, T. I. Pospelova, M. A. Sokolova, A. B. Sudarikov, M. M. Tanashyan, A. G. Turkina, Yu. V. Shatokhin, R. G. Shmakov, E. N. Parovichnikova   +22 more
doaj   +1 more source

CALR mutation profile in Irish patients with myeloproliferative neoplasms

Hematology/Oncology and Stem Cell Therapy, 2016
Insertion and/or deletion mutations of the CALR gene have recently been demonstrated to be the second most common driver mutations in the myeloproliferative neoplasms (MPNs) of essential thrombocythemia (ET) and primary myelofibrosis (PMF).
Karl Haslam, Eibhlin Conneally, Catherine M. Flynn, Mary R. Cahill, Oonagh Gilligan, Derville O'Shea, Stephen E. Langabeer   +6 more
doaj   +1 more source

SENP1-mediated deSUMOylation of JAK2 regulates its kinase activity and platinum drug resistance

Cell Death and Disease, 2021
The JAK2/STAT pathway is hyperactivated in many cancers, and such hyperactivation is associated with a poor clinical prognosis and drug resistance. The mechanism regulating JAK2 activity is complex.
Jing Li, Ruiqin Wu, Mingo M. H. Yung, Jing Sun, Zhuqing Li, Hai Yang, Yi Zhang, Stephanie S. Liu, Annie N. Y. Cheung, Hextan Y. S. Ngan, John C. Braisted, Wei Zheng, Huiqiang Wei, Yingtang Gao, Peter Nemes, Huadong Pei, David W. Chan, Yiliang Li, Wenge Zhu   +18 more
doaj   +1 more source

Infusible Extracellular Matrix Biomaterial Enhances Cell‐Specific Pro‐Repair Responses Following Acute Myocardial Infarction

Advanced Healthcare Materials, EarlyView.
We measure the cell‐specific responses of administering infusible ECM (iECM) in acute myocardial infarction (MI) across multiple timepoints. Using single‐nucleus RNA sequencing and spatial transcriptomics, we measure macrophage activation, fibroblast remodeling, increased vascular development, lymphangiogenesis, cardioprotection, and neurogenesis ...
Joshua M. Mesfin, Alexander Chen, Quincy P. Lyons, Michael B. Nguyen, Maria L. Karkanitsa, Justin Yu, Van K. Ninh, Emily Gardner, Elyse G. Wong, Sriya N. Paleti, Julian Cheng, Benjamin D. Bridgelal, Kate E. Reimold, Selena Cao, Connor Uhre, Colin G. Luo, Zhenxing Fu, Kevin R. King, Karen L. Christman   +18 more
wiley   +1 more source

Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor. [PDF]

PLoS ONE, 2012
The non-receptor tyrosine kinase JAK2 is implicated in a group of myeloproliferative neoplasms including polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
Michael R Marit, Manprit Chohan, Natasha Matthew, Kai Huang, Douglas A Kuntz, David R Rose, Dwayne L Barber   +6 more
doaj   +1 more source